Controversial issues of adjuvant therapy after myomectomy
Uterine fibroids are one of the most common tumors of the female reproductive system. In this article, based on the latest domestic and world publications and clinical recommendations of the Russian Federation, the issues of adjuvant therapy in patients with uterine fibroids after myomectomy (the use of GnRH agonists-antagonist and selective progesterone receptor modulators — SPRM) are highlighted.
Authors
- T.A. Glebov (ORCID: https://orcid.org/0000-0001-6816-5360)
- D.R. Kotsuba (ORCID: https://orcid.org/0000-0003-2305-4493)
- A.A. Kochetkova (ORCID: https://orcid.org/0009-0004-4403-9350)
- E.L. Babunashvili (ORCID: https://orcid.org/0000-0002-3580-7221)
- Е. Н. Карева (ORCID: https://orcid.org/0000-0002-9441-3468)
- N.A. Shchukina (ORCID: https://orcid.org/0000-0003-2274-4070)
Institutions
- Pirogov Russian National Research Medical University (RU)
- Moscow Regional Research Institute of Obstetrics and Gynecology (RU)
Publication Details
- Journal
- Russian Bulletin of Obstetrician-Gynecologist
- Published
- 2024-10-22
- DOI
- https://doi.org/10.17116/rosakush202424051101
- Primary Topic
- Uterine Myomas and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00